Ammonia Diversion Sparks Pharma Concerns

The recent advisory prioritizing surplus ammonia for the fertilizer sector is set to introduce significant cost pressures and supply chain volatility for India's pharmaceutical industry. This directive, while aimed at securing fertilizer production, is creating an input squeeze for drugmakers needing ammonia for crucial API synthesis.

Ammonia Allocation Tightens for Pharma

A government advisory now mandates that all urea manufacturing units must sell surplus ammonia exclusively for fertilizer production, prioritizing subsidized fertilizer manufacturers. This aligns with a March 9th order that reserves natural gas for fertilizer plants, naming them Priority Sector II recipients. Pharmexcil Chairman Namit Joshi warned this diversion will cause shortages within the pharmaceutical sector. This comes as the Nifty Pharma index hit a 52-week high, largely due to rising API costs and existing supply chain disruptions. The market reaction highlights the sector's sensitivity to rising input costs and raw material availability issues.

Pharma's Reliance on Ammonia for APIs

Ammonia is a fundamental building block for synthesizing many APIs, intermediates, and drug formulations. Diverting ammonia to fertilizers poses a dual threat: scarcity and inevitable price hikes for this critical raw material. This compounds existing challenges. Geopolitical tensions have already raised freight, insurance, and other input costs, contributing to a roughly 30% surge in API costs by March 2026. India is a global API powerhouse, ranking third worldwide and supplying over 50% of global demand, but its reliance on imported raw materials is a vulnerability. The regulatory shift risks further inflating production costs, potentially eroding India's global competitive edge. Meanwhile, India is advancing green ammonia initiatives, with recent auctions showing domestic prices around $600/mt, aiming for self-reliance. This contrasts with conventional (grey) ammonia, which faces higher international prices and supply risks. However, the immediate concern is securing ammonia for existing production chains.

Regulatory Risk Exposes Supply Chain Weakness

The advisory highlights a key vulnerability: India's pharma sector depends on commodity chemicals whose allocation can shift with national policy. Unlike competitors with integrated supply chains, Indian API makers heavily reliant on ammonia from urea production face a significant sourcing gap. Pharmexcil previously flagged depleted inventories of chemicals like propylene, methanol, and ammonia due to geopolitical disruptions, showing supply chain fragility. The Natural Gas (Supply Regulation) Order, 2026, allocates 70% of gas needs to fertilizer plants, establishing a hierarchy where pharmaceutical inputs are secondary. Though India is a dominant API producer, its competitive edge risks erosion if foundational inputs like ammonia become unreliable or too expensive due to regulatory directives. This could disrupt supplier relationships and undermine India's 'pharmacy of the world' standing by impacting global supply of essential medicines. Leading Indian pharma companies like Divi's Laboratories (P/E 68.23), Sun Pharmaceutical Industries (P/E 39.72), and Dr. Reddy's Laboratories (P/E 19.91) have high valuations, making them sensitive to profit margin squeezes from rising input costs.

Industry Outlook Amid Ammonia Uncertainty

Analysts project mixed financial performance for India's pharma sector in FY26. While sector revenue is expected to grow about 12%, net profit is forecast to decline 14% year-on-year, mainly due to rising input costs and market shifts. The recent ammonia allocation directive adds complexity and uncertainty, potentially affecting profit margins and export commitments if not resolved quickly. India's commitment to developing green ammonia capacity offers long-term supply stability, but securing ammonia for current production remains an immediate industry concern.